Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166442905> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W3166442905 endingPage "S217" @default.
- W3166442905 startingPage "S217" @default.
- W3166442905 abstract "A small (6.5 million EUR reimbursement cost in Poland in 2018) pharmaceutical company was under pressure by German HQ to increase the official price of Novo-Helisen Depot (NHD) by est. 2 times to catch up with other European countries prices. The drug is indicated for dust mites allergen immunotherapy with no reimbursed equivalents in Poland. This study aims to present the case of how unconventional transparency-based approach helped to achieve a seemingly impossibly large price increase which could potentially result in 8 million EUR budget impact. We analysed documents made public either directly by the company or by the Foundation for Transparency and Predictability of Administrative Decisions. Having submitted on 2019-05-15 the applications (1) to increase NHD initial set price by 128%, (2) to increase NHD one-vial maintenance set price by 228%, (3) to reimburse NHD two-vials maintenance set with a price per vial 228% higher than the reimbursed product price, the company published unredacted argumentation to MoH at https://allergopharmanexter.pl/application/files/5715/5860/5403/Pismo_do_MZ.pdf. They also sponsored the press conference “Does the Minister of Health in Poland Have the Absolute Power in the Reimbursement Proceedings?” on 2019-09-12 during which the Foundation’s president and first author of this study highlighted MoH failures to proceed lawfully based on administrative documents shared by the company (available at https://www.dlaprzejrzystosci.pl/pytanie-z-konferencji-czy-minister-zdrowia-jest-wladca-absolutnym-refundacji-w-polsce-ciagle-aktualne/). Just a month later on 2019-10-14 the Minister of Health took a positive decision to reimburse the two-vials maintenance set with ex-factory price per vial 168% higher than the most recent official reimbursed price (490.00PLN vs 183.10PLN), without a content-related justification although the company provided it. In countries like Poland where positive reimbursement decisions on drugs and their prices lack content-related justification smaller companies may use openness and transparency to communicate the rational justification of their applications and to obtain fair decisions which otherwise apparently would not be achieved." @default.
- W3166442905 created "2021-06-22" @default.
- W3166442905 creator A5020337304 @default.
- W3166442905 date "2021-06-01" @default.
- W3166442905 modified "2023-09-25" @default.
- W3166442905 title "PRS25 Transparency Helped a Small Pharmaceutical Company to Have the Price of Their Drug with Few Million Euro Annual Revenue in Poland Practically Increased by 168% by the Minister of Health - a Case Study of Publicly Available Documents from Administrative Proceedings on Novo-Helisen Depot" @default.
- W3166442905 doi "https://doi.org/10.1016/j.jval.2021.04.1089" @default.
- W3166442905 hasPublicationYear "2021" @default.
- W3166442905 type Work @default.
- W3166442905 sameAs 3166442905 @default.
- W3166442905 citedByCount "0" @default.
- W3166442905 crossrefType "journal-article" @default.
- W3166442905 hasAuthorship W3166442905A5020337304 @default.
- W3166442905 hasBestOaLocation W31664429051 @default.
- W3166442905 hasConcept C121955636 @default.
- W3166442905 hasConcept C144133560 @default.
- W3166442905 hasConcept C154775046 @default.
- W3166442905 hasConcept C160735492 @default.
- W3166442905 hasConcept C166957645 @default.
- W3166442905 hasConcept C17744445 @default.
- W3166442905 hasConcept C195487862 @default.
- W3166442905 hasConcept C199539241 @default.
- W3166442905 hasConcept C205649164 @default.
- W3166442905 hasConcept C2779703844 @default.
- W3166442905 hasConcept C2780233690 @default.
- W3166442905 hasConceptScore W3166442905C121955636 @default.
- W3166442905 hasConceptScore W3166442905C144133560 @default.
- W3166442905 hasConceptScore W3166442905C154775046 @default.
- W3166442905 hasConceptScore W3166442905C160735492 @default.
- W3166442905 hasConceptScore W3166442905C166957645 @default.
- W3166442905 hasConceptScore W3166442905C17744445 @default.
- W3166442905 hasConceptScore W3166442905C195487862 @default.
- W3166442905 hasConceptScore W3166442905C199539241 @default.
- W3166442905 hasConceptScore W3166442905C205649164 @default.
- W3166442905 hasConceptScore W3166442905C2779703844 @default.
- W3166442905 hasConceptScore W3166442905C2780233690 @default.
- W3166442905 hasLocation W31664429051 @default.
- W3166442905 hasOpenAccess W3166442905 @default.
- W3166442905 hasPrimaryLocation W31664429051 @default.
- W3166442905 hasRelatedWork W2063338679 @default.
- W3166442905 hasRelatedWork W2105001751 @default.
- W3166442905 hasRelatedWork W2333526246 @default.
- W3166442905 hasRelatedWork W2411636977 @default.
- W3166442905 hasRelatedWork W2770742088 @default.
- W3166442905 hasRelatedWork W2887091436 @default.
- W3166442905 hasRelatedWork W2969335107 @default.
- W3166442905 hasRelatedWork W4283793902 @default.
- W3166442905 hasRelatedWork W58856560 @default.
- W3166442905 hasRelatedWork W3087664850 @default.
- W3166442905 hasVolume "24" @default.
- W3166442905 isParatext "false" @default.
- W3166442905 isRetracted "false" @default.
- W3166442905 magId "3166442905" @default.
- W3166442905 workType "article" @default.